Publications by authors named "J Vinje"

Norovirus is the leading cause of acute gastroenteritis (AGE) globally. Few longitudinal studies have assessed norovirus-associated AGE incidence across age groups in community settings in Latin America. During April 2015-April 2019, active surveillance for AGE among community members of all ages was conducted through household visits two to three times per week in San Jeronimo, Cusco, Peru.

View Article and Find Full Text PDF

We investigated a suspected norovirus outbreak associated with a wedding reception in Wisconsin in May 2015. Fifty-six of 106 (53%) wedding attendees were interviewed, and 23 (41%) reported symptoms consistent with norovirus infection. A retrospective cohort study identified fruit salad as the likely vehicle of infection (risk ratio 3.

View Article and Find Full Text PDF

We report an increase in GII.17 norovirus outbreaks and sporadic infections of acute gastroenteritis in Austria, Germany, France, Ireland, the Netherlands, England and the United States during the 2023/24 season. A decrease in GII.

View Article and Find Full Text PDF

Background: Astrovirus is a leading cause of acute gastroenteritis in children worldwide. However, few prospective studies have analyzed astrovirus in community-dwelling pediatric populations in low- and middle-income countries.

Methods: We assessed the incidence, risk factors, clinical characteristics, genotypes, viral coinfections, and time distribution of astrovirus gastroenteritis in 443 healthy Nicaraguan children born in 2017 to 2018 who were followed for 36 months.

View Article and Find Full Text PDF
Article Synopsis
  • mRNA-based COVID-19 vaccines, like Moderna's, are effective in reducing severe COVID-19 outcomes and have been studied for their immune responses, but less is known about antibody presence in saliva and mucosal fluids.
  • A study involving 203 CDC staff members was conducted to analyze the salivary immune response by collecting saliva samples before and after vaccination, focusing on specific antibodies (IgA and IgG) against SARS-CoV-2.
  • Results showed that salivary IgA levels peaked shortly after each vaccine dose, while IgG levels increased after the first dose, peaked after the second, and remained elevated for at least two months; however, more research is needed for long-term antibody tracking beyond this period.
View Article and Find Full Text PDF